CK Life Sciences (00775) subsidiary SunPur Medicine Technology will present research data on the development of therapeutic cancer vaccines at the AACR 2026 Annual Meeting.

CK Life Sciences (00775) announced that its subsidiary, Sequencio Therapeutics Company Limited, will showcase research data on therapeutic cancer vaccine development at the American Association for Cancer Research (AACR) 2026 Annual Meeting in San Diego, United States. Five research abstracts will focus on preclinical research data on cancer vaccine development, targeting p53 neoantigen, IGF1R (insulin-like growth factor 1 receptor), B7-H3 (B7 homolog 3), TROP2, and Claudin 6 vaccines. This marks the first important scientific achievement announced by Sequencio Therapeutics since its establishment, demonstrating significant progress in the development of next-generation cancer vaccine technology using the proprietary TrueHLA Epitope-to-Efficacy conversion design framework. This framework enables rational data-driven vaccine development across circular RNA, messenger RNA, peptide, and protein technology platforms. Overall, the research presented shares a common theme: rational design cancer vaccines showing strong immunogenicity and significant anti-tumor activity in preclinical models targeting multiple tumor antigens. The data presented in the publication fully validates the advantage of Sequencio Therapeutics from antigen selection to functional immune response and tumor control. Based on this, Sequencio Therapeutics is accelerating the development of the most promising research projects, applying for new drug clinical trial applications (IND) supportive studies, and aims to advance selected candidate vaccines into early clinical development stages through strategic partnerships and global collaborations.